| Record Information |
|---|
| Version | 1.0 |
|---|
| Creation date | 2010-04-08 22:04:37 UTC |
|---|
| Update date | 2020-09-17 15:38:25 UTC |
|---|
| Primary ID | FDB000567 |
|---|
| Secondary Accession Numbers | Not Available |
|---|
| Chemical Information |
|---|
| FooDB Name | L-DOPA |
|---|
| Description | L-Dopa, also known as dopar or dopaston, belongs to the class of organic compounds known as tyrosine and derivatives. Tyrosine and derivatives are compounds containing tyrosine or a derivative thereof resulting from reaction of tyrosine at the amino group or the carboxy group, or from the replacement of any hydrogen of glycine by a heteroatom. L-Dopa is a very strong basic compound (based on its pKa). L-Dopa exists in all living organisms, ranging from bacteria to humans. Within humans, L-dopa participates in a number of enzymatic reactions. In particular, L-dopa and tetrahydrobiopterin can be converted into dopamine and 4a-hydroxytetrahydrobiopterin through its interaction with the enzyme aromatic-L-amino-acid decarboxylase. In addition, L-dopa can be converted into dopaquinone; which is catalyzed by the enzyme tyrosinase. In humans, L-dopa is involved in the metabolic disorder called hawkinsinuria. L-Dopa is an odorless tasting compound. Outside of the human body, L-Dopa is found, on average, in the highest concentration within a few different foods, such as broad beans, swiss chards, and yellow wax beans and in a lower concentration in spinachs, garden onions, and green beans. L-Dopa has also been detected, but not quantified in, several different foods, such as chicory roots, bitter gourds, mustard spinachs, pistachio, and savoy cabbages. This could make L-dopa a potential biomarker for the consumption of these foods. L-Dopa is a potentially toxic compound. L-Dopa, with regard to humans, has been found to be associated with several diseases such as eosinophilic esophagitis and alzheimer's disease; L-dopa has also been linked to several inborn metabolic disorders including aromatic l-amino acid decarboxylase deficiency and sepiapterin reductase deficiency. An optically active form of dopa having L-configuration. |
|---|
| CAS Number | 59-92-7 |
|---|
| Structure | |
|---|
| Synonyms | | Synonym | Source |
|---|
| (-)-3-(3,4-Dihydroxyphenyl)-L-alanine | ChEBI | | (-)-Dopa | ChEBI | | 3,4-Dihydroxy-L-phenylalanine | ChEBI | | 3,4-DIHYDROXYPHENYLALANINE | ChEBI | | 3-Hydroxy-L-tyrosine | ChEBI | | beta-(3,4-Dihydroxyphenyl)-L-alanine | ChEBI | | beta-(3,4-Dihydroxyphenyl)alanine | ChEBI | | Dihydroxy-L-phenylalanine | ChEBI | | Dopar | ChEBI | | L-beta-(3,4-Dihydroxyphenyl)alanine | ChEBI | | Levodopa | ChEBI | | Levodopum | ChEBI | | b-(3,4-Dihydroxyphenyl)-L-alanine | Generator | | Β-(3,4-dihydroxyphenyl)-L-alanine | Generator | | b-(3,4-Dihydroxyphenyl)alanine | Generator | | Β-(3,4-dihydroxyphenyl)alanine | Generator | | L-b-(3,4-Dihydroxyphenyl)alanine | Generator | | L-Β-(3,4-dihydroxyphenyl)alanine | Generator | | (2S)-2-Amino-3-(3,4-dihydroxyphenyl)propanoate | HMDB | | (2S)-2-Amino-3-(3,4-dihydroxyphenyl)propanoic acid | HMDB | | 3,4-Dihydroxyphenyl-L-alanine | HMDB | | 3-(3,4-Dihydroxyphenyl)-L-alanine | HMDB | | b-(3,4-Dihydroxyphenyl)-a-L-alanine | HMDB | | Bendopa | HMDB | | beta-(3,4-Dihydroxyphenyl)-alpha-L-alanine | HMDB | | Cidandopa | HMDB | | Dihydroxyphenylalanine | HMDB | | Dopaflex | HMDB | | Dopaidan | HMDB | | Dopal | HMDB | | Dopalina | HMDB | | Doparkine | HMDB | | Doparl | HMDB | | Dopasol | HMDB | | Dopaston | HMDB | | Dopastone | HMDB | | Dopastral | HMDB | | Dopicar | HMDB | | Doprin | HMDB | | Eldopal | HMDB | | Eldopar | HMDB | | Eldopatec | HMDB | | Eurodopa | HMDB | | Helfo-dopa | HMDB | | Insulamina | HMDB | | L-(-)-Dopa | HMDB | | L-3-(3,4-Dihydroxyphenyl)-alanine | HMDB | | L-4-5-Dihydroxyphenylalanine | HMDB | | L-b-(3,4-Dihydroxyphenyl)-a-alanine | HMDB | | L-beta-(3,4-Dihydroxyphenyl)-alpha-alanine | HMDB | | L-Dihydroxyphenylalanine | HMDB | | Laradopa | HMDB | | Larodopa | HMDB | | Ledopa | HMDB | | Levedopa | HMDB | | Levopa | HMDB | | Maipedopa | HMDB | | Parda | HMDB | | Pardopa | HMDB | | Prodopa | HMDB | | Syndopa | HMDB | | Veldopa | HMDB | | Weldopa | HMDB | | 3 Hydroxy L tyrosine | HMDB | | Roche brand OF levodopa | HMDB | | L 3,4 Dihydroxyphenylalanine | HMDB | | L-3,4-Dihydroxyphenylalanine | HMDB | | Medphano brand OF levodopa | HMDB | | L Dopa | HMDB | | Roberts brand OF levodopa | HMDB | | (-)-(3,4-Dihydroxyphenyl)alanine | biospider | | (-)-3-(3,4-dihydroxyphenyl)-L-alanine | biospider | | (-)-DOPA | biospider | | (2S)-2-amino-3-(3,4-dihydroxyphenyl)propanoate | biospider | | (2S)-2-amino-3-(3,4-dihydroxyphenyl)propanoic acid | biospider | | β-(3,4-Dihydroxyphenyl)-L-alanine | biospider | | β-(3,4-Dihydroxyphenyl)alanine | biospider | | 2-Amino-3-(3,4-dihydroxyphenyl)propanoic acid; L-form | db_source | | Alanine, 3-(3,4-dihydroxyphenyl)-, (-)- | biospider | | Alanine, 3-(3,4-dihydroxyphenyl)-, L- | biospider | | DOPA | biospider | | L-(-)-DOPA | biospider | | L-(3, 4-Dihydroxyphenyl)alanine | biospider | | L-(3,4-Dihydroxyphenyl)-α-alanine | biospider | | L-(3,4-Dihydroxyphenyl)alanine | biospider | | L-β-(3,4-Dihydroxyphenyl)alanine | biospider | | L-3-(3,4-dihydroxyphenyl)-Alanine | biospider | | L-3-(3,4-Dihydroxyphenyl)alanine | biospider | | L-3-Hydroxytyrosine | biospider | | L-dihydroxyphenylalanine | biospider | | L-DOPA | biospider | | L-Tyrosine, 3-hydroxy- | biospider | | L-β-(3,4-dihydroxyphenyl)alanine | Generator | | Levodopa, BAN, INN, JAN, USAN | db_source | | β-(3,4-dihydroxyphenyl)-L-alanine | Generator | | β-(3,4-dihydroxyphenyl)alanine | Generator |
|
|---|
| Predicted Properties | |
|---|
| Chemical Formula | C9H11NO4 |
|---|
| IUPAC name | (2S)-2-amino-3-(3,4-dihydroxyphenyl)propanoic acid |
|---|
| InChI Identifier | InChI=1S/C9H11NO4/c10-6(9(13)14)3-5-1-2-7(11)8(12)4-5/h1-2,4,6,11-12H,3,10H2,(H,13,14)/t6-/m0/s1 |
|---|
| InChI Key | WTDRDQBEARUVNC-LURJTMIESA-N |
|---|
| Isomeric SMILES | N[C@@H](CC1=CC(O)=C(O)C=C1)C(O)=O |
|---|
| Average Molecular Weight | 197.1879 |
|---|
| Monoisotopic Molecular Weight | 197.068807845 |
|---|
| Classification |
|---|
| Description | Belongs to the class of organic compounds known as tyrosine and derivatives. Tyrosine and derivatives are compounds containing tyrosine or a derivative thereof resulting from reaction of tyrosine at the amino group or the carboxy group, or from the replacement of any hydrogen of glycine by a heteroatom. |
|---|
| Kingdom | Organic compounds |
|---|
| Super Class | Organic acids and derivatives |
|---|
| Class | Carboxylic acids and derivatives |
|---|
| Sub Class | Amino acids, peptides, and analogues |
|---|
| Direct Parent | Tyrosine and derivatives |
|---|
| Alternative Parents | |
|---|
| Substituents | - Tyrosine or derivatives
- Phenylalanine or derivatives
- 3-phenylpropanoic-acid
- Alpha-amino acid
- Amphetamine or derivatives
- L-alpha-amino acid
- Catechol
- 1-hydroxy-4-unsubstituted benzenoid
- Aralkylamine
- 1-hydroxy-2-unsubstituted benzenoid
- Phenol
- Monocyclic benzene moiety
- Benzenoid
- Amino acid
- Carboxylic acid
- Monocarboxylic acid or derivatives
- Organic oxide
- Organooxygen compound
- Organonitrogen compound
- Primary amine
- Primary aliphatic amine
- Organic nitrogen compound
- Organic oxygen compound
- Carbonyl group
- Hydrocarbon derivative
- Organopnictogen compound
- Amine
- Aromatic homomonocyclic compound
|
|---|
| Molecular Framework | Aromatic homomonocyclic compounds |
|---|
| External Descriptors | |
|---|
| Ontology |
|---|
|
| Disposition | Route of exposure: Source: Biological location: |
|---|
| Role | Indirect biological role: Environmental role: Industrial application: |
|---|
| Physico-Chemical Properties |
|---|
| Physico-Chemical Properties - Experimental | | Property | Value | Reference |
|---|
| Physical state | Solid | |
|---|
| Physical Description | Not Available | |
|---|
| Mass Composition | C 54.82%; H 5.62%; N 7.10%; O 32.45% | DFC |
|---|
| Melting Point | Mp 285.5° dec. | DFC |
|---|
| Boiling Point | Not Available | |
|---|
| Experimental Water Solubility | 5 mg/mL at 20 oC | YALKOWSKY,SH & DANNENFELSER,RM (1992) |
|---|
| Experimental logP | -2.39 | SANGSTER (1993) |
|---|
| Experimental pKa | 2.32 | |
|---|
| Isoelectric point | Not Available | |
|---|
| Charge | Not Available | |
|---|
| Optical Rotation | [a]20D -12.15 (c, 4 in 1N HCl) | DFC |
|---|
| Spectroscopic UV Data | Not Available | |
|---|
| Density | Not Available | |
|---|
| Refractive Index | Not Available | |
|---|
|
|---|
| Spectra |
|---|
| Spectra | |
|---|
| EI-MS/GC-MS | | Type | Description | Splash Key | View |
|---|
| GC-MS | L-DOPA, 4 TMS, GC-MS Spectrum | splash10-014i-0790000000-b2f7f063a2c8197c7edd | Spectrum | | GC-MS | L-DOPA, non-derivatized, GC-MS Spectrum | splash10-014i-0690000000-622497b3104c6082a45d | Spectrum | | GC-MS | L-DOPA, 4 TMS, GC-MS Spectrum | splash10-00xr-9350000000-b0cc4636931d2de64d81 | Spectrum | | GC-MS | L-DOPA, 4 TMS, GC-MS Spectrum | splash10-014i-0590000000-4474e81e4226bb4e1d4c | Spectrum | | GC-MS | L-DOPA, non-derivatized, GC-MS Spectrum | splash10-014i-0790000000-b2f7f063a2c8197c7edd | Spectrum | | GC-MS | L-DOPA, non-derivatized, GC-MS Spectrum | splash10-014i-0690000000-622497b3104c6082a45d | Spectrum | | GC-MS | L-DOPA, non-derivatized, GC-MS Spectrum | splash10-00xr-9350000000-b0cc4636931d2de64d81 | Spectrum | | GC-MS | L-DOPA, non-derivatized, GC-MS Spectrum | splash10-014i-0590000000-4474e81e4226bb4e1d4c | Spectrum | | GC-MS | L-DOPA, non-derivatized, GC-MS Spectrum | splash10-014i-1890000000-646d209fa1943582a336 | Spectrum | | GC-MS | L-DOPA, non-derivatized, GC-MS Spectrum | splash10-014i-0690000000-720ed87e98a0d9f1721d | Spectrum | | Predicted GC-MS | L-DOPA, non-derivatized, Predicted GC-MS Spectrum - 70eV, Positive | splash10-0fk9-3900000000-266d9baeda773fe1fb22 | Spectrum | | Predicted GC-MS | L-DOPA, 3 TMS, Predicted GC-MS Spectrum - 70eV, Positive | splash10-0002-4193000000-8c76bf85d8a897e9403c | Spectrum | | Predicted GC-MS | L-DOPA, non-derivatized, Predicted GC-MS Spectrum - 70eV, Positive | Not Available | Spectrum | | Predicted GC-MS | L-DOPA, TMS_1_1, Predicted GC-MS Spectrum - 70eV, Positive | Not Available | Spectrum | | Predicted GC-MS | L-DOPA, TMS_1_2, Predicted GC-MS Spectrum - 70eV, Positive | Not Available | Spectrum | | Predicted GC-MS | L-DOPA, TMS_1_3, Predicted GC-MS Spectrum - 70eV, Positive | Not Available | Spectrum | | Predicted GC-MS | L-DOPA, TMS_1_4, Predicted GC-MS Spectrum - 70eV, Positive | Not Available | Spectrum | | Predicted GC-MS | L-DOPA, TMS_2_1, Predicted GC-MS Spectrum - 70eV, Positive | Not Available | Spectrum | | Predicted GC-MS | L-DOPA, TMS_2_2, Predicted GC-MS Spectrum - 70eV, Positive | Not Available | Spectrum | | Predicted GC-MS | L-DOPA, TMS_2_3, Predicted GC-MS Spectrum - 70eV, Positive | Not Available | Spectrum | | Predicted GC-MS | L-DOPA, TMS_2_4, Predicted GC-MS Spectrum - 70eV, Positive | Not Available | Spectrum | | Predicted GC-MS | L-DOPA, TMS_2_5, Predicted GC-MS Spectrum - 70eV, Positive | Not Available | Spectrum | | Predicted GC-MS | L-DOPA, TMS_2_6, Predicted GC-MS Spectrum - 70eV, Positive | Not Available | Spectrum | | Predicted GC-MS | L-DOPA, TMS_2_7, Predicted GC-MS Spectrum - 70eV, Positive | Not Available | Spectrum | | Predicted GC-MS | L-DOPA, TMS_3_2, Predicted GC-MS Spectrum - 70eV, Positive | Not Available | Spectrum |
|
|---|
| MS/MS | | Type | Description | Splash Key | View |
|---|
| MS/MS | LC-MS/MS Spectrum - Quattro_QQQ 10V, Positive (Annotated) | splash10-0uea-0900000000-8eb71aa0cc8622f097a2 | 2012-07-24 | View Spectrum | | MS/MS | LC-MS/MS Spectrum - Quattro_QQQ 25V, Positive (Annotated) | splash10-0a59-2900000000-bf63b9b719959b82b543 | 2012-07-24 | View Spectrum | | MS/MS | LC-MS/MS Spectrum - Quattro_QQQ 40V, Positive (Annotated) | splash10-056r-9300000000-a78b0b31dd33fe8479a7 | 2012-07-24 | View Spectrum | | MS/MS | LC-MS/MS Spectrum - LC-ESI-ITFT (LTQ Orbitrap XL, Thermo Scientfic) , Positive | splash10-0f6t-0911000000-15affa616923dfb9c45a | 2012-08-31 | View Spectrum | | MS/MS | LC-MS/MS Spectrum - LC-ESI-ITFT (LTQ Orbitrap XL, Thermo Scientfic) , Positive | splash10-000i-0900000000-22d8267801d0eb0b73c2 | 2012-08-31 | View Spectrum | | MS/MS | LC-MS/MS Spectrum - LC-ESI-ITFT (LTQ Orbitrap XL, Thermo Scientfic) , Positive | splash10-001i-0900000000-2c310034a1a871502b4c | 2012-08-31 | View Spectrum | | MS/MS | LC-MS/MS Spectrum - LC-ESI-ITFT (LTQ Orbitrap XL, Thermo Scientfic) , Positive | splash10-0udi-0900000000-5e6020c952f741531fcb | 2012-08-31 | View Spectrum | | MS/MS | LC-MS/MS Spectrum - LC-ESI-ITFT (LTQ Orbitrap XL, Thermo Scientfic) , Positive | splash10-0007-0970100000-49594dae82ce73e734e6 | 2012-08-31 | View Spectrum | | MS/MS | LC-MS/MS Spectrum - LC-ESI-ITFT (LTQ Orbitrap XL, Thermo Scientfic) , Positive | splash10-001i-0900000000-2183a68f58b951f3f1c7 | 2012-08-31 | View Spectrum | | MS/MS | LC-MS/MS Spectrum - LC-ESI-ITFT (LTQ Orbitrap XL, Thermo Scientfic) , Positive | splash10-03di-0900000000-0030db588fbd92c5b761 | 2012-08-31 | View Spectrum | | MS/MS | LC-MS/MS Spectrum - LC-ESI-ITFT (LTQ Orbitrap XL, Thermo Scientfic) , Positive | splash10-0006-0090000000-544615463a975baae9e4 | 2012-08-31 | View Spectrum | | MS/MS | LC-MS/MS Spectrum - LC-ESI-ITFT (LTQ Orbitrap XL, Thermo Scientfic) , Negative | splash10-0002-0729111000-0a20b01f58fff8ad7ef0 | 2012-08-31 | View Spectrum | | MS/MS | LC-MS/MS Spectrum - LC-ESI-ITFT (LTQ Orbitrap XL, Thermo Scientfic) , Negative | splash10-004i-0900000000-c8095a31ed4b3dbbc646 | 2012-08-31 | View Spectrum | | MS/MS | LC-MS/MS Spectrum - LC-ESI-ITFT (LTQ Orbitrap XL, Thermo Scientfic) , Negative | splash10-03di-0190000000-41515cba3a6929721859 | 2012-08-31 | View Spectrum | | MS/MS | LC-MS/MS Spectrum - LC-ESI-ITFT (LTQ Orbitrap XL, Thermo Scientfic) , Negative | splash10-0002-0900000000-8074c509ef5bae1129fc | 2012-08-31 | View Spectrum | | MS/MS | LC-MS/MS Spectrum - LC-ESI-ITFT (LTQ Orbitrap XL, Thermo Scientfic) , Negative | splash10-0006-0502193020-497bfad7ba247159ca00 | 2012-08-31 | View Spectrum | | MS/MS | LC-MS/MS Spectrum - LC-ESI-ITFT (LTQ Orbitrap XL, Thermo Scientfic) , Negative | splash10-004i-0900000000-0b0d4b6dcb7f1fa24e1a | 2012-08-31 | View Spectrum | | MS/MS | LC-MS/MS Spectrum - LC-ESI-ITFT (LTQ Orbitrap XL, Thermo Scientfic) , Negative | splash10-004i-0029800000-05f40324c8c1fec7963a | 2012-08-31 | View Spectrum | | MS/MS | LC-MS/MS Spectrum - LC-ESI-ITFT (LTQ Orbitrap XL, Thermo Scientfic) , Negative | splash10-0006-0000090000-c0cd80185ce47b30e5fe | 2012-08-31 | View Spectrum | | MS/MS | LC-MS/MS Spectrum - LC-ESI-QTOF (UPLC Q-Tof Premier, Waters) , Positive | splash10-0002-0900000000-df116b84981cf4a1371a | 2012-08-31 | View Spectrum | | MS/MS | LC-MS/MS Spectrum - LC-ESI-QTOF (UPLC Q-Tof Premier, Waters) 30V, Positive | splash10-0f6t-0900000000-1c1c39a8880442ea18df | 2012-08-31 | View Spectrum | | Predicted MS/MS | Predicted LC-MS/MS Spectrum - 10V, Positive | splash10-0udj-0900000000-cf54b26df05181b0d2fc | 2017-07-26 | View Spectrum | | Predicted MS/MS | Predicted LC-MS/MS Spectrum - 20V, Positive | splash10-0udi-0900000000-d506f2673b114b8e38d2 | 2017-07-26 | View Spectrum | | Predicted MS/MS | Predicted LC-MS/MS Spectrum - 40V, Positive | splash10-00di-8900000000-1699873cb7650f62b5bc | 2017-07-26 | View Spectrum | | Predicted MS/MS | Predicted LC-MS/MS Spectrum - 10V, Negative | splash10-0002-0900000000-a0d81bfc4868b0d1cbf9 | 2017-07-26 | View Spectrum |
|
|---|
| NMR | | Type | Description | | View |
|---|
| 1D NMR | 1H NMR Spectrum (1D, 500 MHz, H2O, experimental) | | Spectrum | | 1D NMR | 1H NMR Spectrum (1D, 100 MHz, D2O, predicted) | | Spectrum | | 1D NMR | 13C NMR Spectrum (1D, 100 MHz, D2O, predicted) | | Spectrum | | 1D NMR | 1H NMR Spectrum (1D, 200 MHz, D2O, predicted) | | Spectrum | | 1D NMR | 13C NMR Spectrum (1D, 200 MHz, D2O, predicted) | | Spectrum | | 1D NMR | 1H NMR Spectrum (1D, 300 MHz, D2O, predicted) | | Spectrum | | 1D NMR | 13C NMR Spectrum (1D, 300 MHz, D2O, predicted) | | Spectrum | | 1D NMR | 1H NMR Spectrum (1D, 400 MHz, D2O, predicted) | | Spectrum | | 1D NMR | 13C NMR Spectrum (1D, 400 MHz, D2O, predicted) | | Spectrum | | 1D NMR | 1H NMR Spectrum (1D, 500 MHz, D2O, predicted) | | Spectrum | | 1D NMR | 13C NMR Spectrum (1D, 500 MHz, D2O, predicted) | | Spectrum | | 1D NMR | 1H NMR Spectrum (1D, 600 MHz, D2O, predicted) | | Spectrum | | 1D NMR | 13C NMR Spectrum (1D, 600 MHz, D2O, predicted) | | Spectrum | | 1D NMR | 1H NMR Spectrum (1D, 700 MHz, D2O, predicted) | | Spectrum | | 1D NMR | 13C NMR Spectrum (1D, 700 MHz, D2O, predicted) | | Spectrum | | 1D NMR | 1H NMR Spectrum (1D, 800 MHz, D2O, predicted) | | Spectrum | | 1D NMR | 13C NMR Spectrum (1D, 800 MHz, D2O, predicted) | | Spectrum | | 1D NMR | 1H NMR Spectrum (1D, 900 MHz, D2O, predicted) | | Spectrum | | 1D NMR | 13C NMR Spectrum (1D, 900 MHz, D2O, predicted) | | Spectrum | | 1D NMR | 1H NMR Spectrum (1D, 1000 MHz, D2O, predicted) | | Spectrum | | 1D NMR | 13C NMR Spectrum (1D, 1000 MHz, D2O, predicted) | | Spectrum | | 2D NMR | [1H, 13C]-HSQC NMR Spectrum (2D, 600 MHz, H2O, experimental) | | Spectrum |
|
|---|
| External Links |
|---|
| ChemSpider ID | 5824 |
|---|
| ChEMBL ID | CHEMBL1009 |
|---|
| KEGG Compound ID | C00355 |
|---|
| Pubchem Compound ID | 6047 |
|---|
| Pubchem Substance ID | Not Available |
|---|
| ChEBI ID | 15765 |
|---|
| Phenol-Explorer ID | Not Available |
|---|
| DrugBank ID | DB01235 |
|---|
| HMDB ID | HMDB00181 |
|---|
| CRC / DFC (Dictionary of Food Compounds) ID | HHZ68-O:BDR85-N |
|---|
| EAFUS ID | Not Available |
|---|
| Dr. Duke ID | L-DOPA|DOPA |
|---|
| BIGG ID | 34719 |
|---|
| KNApSAcK ID | C00001357 |
|---|
| HET ID | DAH |
|---|
| Food Biomarker Ontology | Not Available |
|---|
| VMH ID | Not Available |
|---|
| Flavornet ID | Not Available |
|---|
| GoodScent ID | rw1253531 |
|---|
| SuperScent ID | Not Available |
|---|
| Wikipedia ID | L-Dopa |
|---|
| Phenol-Explorer Metabolite ID | Not Available |
|---|
| Duplicate IDS | Not Available |
|---|
| Old DFC IDS | Not Available |
|---|
| Associated Foods |
|---|
| Food | Content Range | Average | Reference |
|---|
| Food | | | Reference |
|---|
|
| Biological Effects and Interactions |
|---|
| Health Effects / Bioactivities | | Descriptor | ID | Definition | Reference |
|---|
| Analgesic | 35480 | An agent that relieves pain by reducing or blocking pain signals in the brain, commonly used to manage acute or chronic pain, inflammation, and fever, with therapeutic applications in surgery, injury, and disease treatment. | DUKE | | Anorexic | 50780 | An agent that suppresses appetite, reducing food intake. Its biological role involves regulating hunger and satiety signals. Therapeutically, anorexics are used to treat obesity and weight-related disorders, promoting weight loss and improving metabolic health. Key medical uses include managing exogenous obesity and related conditions, such as diabetes and hypertension. | DUKE | | Antidote | 50247 | An agent that counteracts a poison or toxin, neutralizing its harmful effects. It plays a biological role in reversing toxicity, and has therapeutic applications in treating poisoning, overdose, and envenomation. Key medical uses include emergency treatment for snake bites, drug overdose, and chemical exposure. | DUKE | | Anti-encephalopathic | 52217 | An agent that protects against encephalopathy, a brain disease or damage. It plays a biological role in reducing brain inflammation and oxidative stress. Therapeutically, it is used to manage conditions such as hepatic encephalopathy, traumatic brain injury, and stroke, helping to improve cognitive function and overall brain health. | DUKE | | Anti feedant | | A substance that inhibits normal feeding behavior, found in certain plants, deterring insects and animals from consuming them. Its therapeutic applications include pest control, while key medical uses involve managing insect-borne diseases and reducing crop damage. | DUKE | | Anti morphinic | | An agent that inhibits the action of morphine, reducing its analgesic and euphoric effects. It plays a biological role in regulating opioid activity. Therapeutically, it has applications in managing opioid overdose, dependence, and withdrawal. Key medical uses include reversing morphine-induced respiratory depression and treating opioid addiction. | DUKE | | Anti neuroleptic | 35470 | An agent that blocks dopamine receptors, reducing psychotic symptoms. Therapeutically, it is used to manage schizophrenia, bipolar disorder, and other psychiatric conditions, helping to alleviate hallucinations, delusions, and agitation. | DUKE | | Anti-Parkinsonian | 48407 | An agent that alleviates symptoms of Parkinson's disease, enhancing dopamine levels and improving motor function, commonly used to manage tremors, rigidity, and bradykinesia in neurodegenerative disorders. | DUKE | | Anti-reserpine | | An agent that counteracts the effects of reserpine, increasing neurotransmitter levels. Therapeutically, it's used to manage reserpine-induced side effects, such as depression, and has applications in treating Parkinson's disease, schizophrenia, and other neurological disorders. | DUKE | | Anti tremor | 52217 | An agent that reduces muscle tremors, commonly used in managing Parkinson's disease, essential tremor, and other movement disorders, to improve motor function and quality of life. | DUKE | | Aphrodisiac | | A substance that stimulates sexual desire, playing a biological role in enhancing libido. It has therapeutic applications in treating sexual dysfunction and key medical uses in managing conditions such as erectile dysfunction and low sex drive. | DUKE | | Arrhythmigenic | 38070 | An agent that induces or exacerbates irregular heart rhythms, often used in medical research to study cardiac arrhythmias. Therapeutically, it has limited applications, but can be used to test the efficacy of anti-arrhythmic medications or in cardiac stress tests to diagnose underlying heart conditions. | DUKE | | Cardiovascular | 38070 | A system that transports blood, oxygen, and nutrients throughout the body, playing a crucial role in overall health. Therapeutically, cardiovascular agents manage conditions like hypertension, heart failure, and atherosclerosis, with key medical uses including regulating blood pressure, preventing blood clots, and improving cardiac function. | DUKE | | Central nervous system active | 35470 | An agent that affects brain and spinal cord function, influencing mood, cognition, and physical responses. Therapeutically, it's used to manage neurological and psychiatric disorders, such as depression, anxiety, and insomnia, by modulating neurotransmitter activity and neural pathways. | DUKE | | Depressant | | An agent that lowers neurotransmission levels, reducing arousal or stimulation in the brain, used therapeutically to treat anxiety, insomnia, and seizures, and medically to induce sedation and relieve symptoms of certain conditions. | DUKE | | Diuretic | 35498 | An agent that increases urine production, helping remove excess fluids and salts from the body. It plays a key biological role in regulating fluid balance and blood pressure. Therapeutically, diuretics are used to treat conditions such as hypertension, edema, and heart failure, helping reduce swelling and lower blood pressure. | DUKE | | Dopaminergic | 48560 | An agent that stimulates or regulates dopamine activity, playing a key role in movement, motivation, and reward processing. Therapeutically, dopaminergic agents are used to manage Parkinson's disease, restless leg syndrome, and certain psychiatric disorders, such as schizophrenia and depression. | DUKE | | Emetic | | An agent that induces vomiting, playing a biological role in expelling toxins from the body. Therapeutically, it is used to treat poisoning, overdose, or gastrointestinal obstruction. Key medical uses include managing drug toxicity and aiding in stomach pumping procedures. | DUKE | | Hallucinogen | 35499 | A psychoactive agent that alters perception, thought, and mood, affecting serotonin and dopamine levels. It has a biological role in modifying brain chemistry. Therapeutically, it's explored for treating mental health disorders, such as depression and PTSD. Key medical uses include research in anxiety and addiction treatment, with potential for therapeutic breakthroughs in psychiatric care. | DUKE | | Hypertensive | | An agent that increases blood pressure, used therapeutically to treat hypotension (low blood pressure) and shock, and medically to manage conditions such as orthostatic hypotension and postural hypotension. | DUKE | | Hypotensive | | An agent that lowers blood pressure, playing a biological role in regulating cardiovascular function. Therapeutically, it's used to manage hypertension, heart failure, and angina, with key medical applications in preventing stroke, kidney disease, and cardiac complications. | DUKE | | Insectifuge | 24852 | A substance that repels insects, playing a biological role in plant defense. Therapeutically, it has applications in preventing insect-borne diseases. Key medical uses include topical repellents for malaria, dengue fever, and other vector-borne illnesses, reducing the risk of transmission. | DUKE | | Miotic | 51068 | An agent that constricts the pupils, reducing intraocular pressure. It plays a biological role in regulating eye function and has therapeutic applications in treating glaucoma, uveitis, and other eye disorders, making it a key medical use in ophthalmology. | DUKE | | Natriuretic | | An agent that promotes the excretion of sodium in the urine, aiding in blood pressure regulation and fluid balance. It plays a biological role in managing hypertension and heart failure, with therapeutic applications in treating edema and cardiovascular diseases. Key medical uses include diuretic therapy and management of congestive heart failure. | DUKE | | Neurotoxic | 50910 | A substance that damages or destroys nerve cells, disrupting normal brain function. It has no therapeutic applications, but is used in research to study neurodegenerative diseases. Key medical uses include understanding and developing treatments for conditions like Alzheimer's and Parkinson's diseases, where neurotoxicity plays a role. | CHEBI |
|
|---|
| Enzymes | | Name | Gene Name | UniProt ID |
|---|
| Aromatic-L-amino-acid decarboxylase | DDC | P20711 | | Tyrosine 3-monooxygenase | TH | P07101 | | D(2) dopamine receptor | DRD2 | P14416 | | D(4) dopamine receptor | DRD4 | P21917 |
|
|---|
| Pathways | |
|---|
| Metabolism | Not Available |
|---|
| Biosynthesis | Not Available |
|---|
| Organoleptic Properties |
|---|
| Flavours | | Flavor | Citations |
|---|
| odorless |
- The Good Scents Company (2009). Flavor and fragrance information catalog. <http://www.thegoodscentscompany.com/allprod.html> Accessed 15.10.23.
|
|
|---|
| Files |
|---|
| MSDS | show |
|---|
| References |
|---|
| Synthesis Reference | Not Available |
|---|
| General Reference | Not Available |
|---|
| Content Reference | — Shinbo, Y., et al. 'KNApSAcK: a comprehensive species-metabolite relationship database.' Plant Metabolomics. Springer Berlin Heidelberg, 2006. 165-181. — Duke, James. 'Dr. Duke's Phytochemical and Ethnobotanical Databases. United States Department of Agriculture.' Agricultural Research Service, Accessed April 27 (2004).
|
|---|